Tenet Reports Second Quarter 2022 Results; Reaffirms 2022 Adjusted EBITDA Outlook
Tenet Healthcare Corporation (THC) reported Q2 2022 net income of $38 million, down from $120 million in Q2 2021. Adjusted EBITDA rose to $843 million, slightly up from $834 million year-over-year. Diluted earnings per share dropped to $0.35 from $1.11 in Q2 2021. A cybersecurity incident negatively impacted adjusted admissions by 5.3%. The acquisition of USPI's remaining 5% stake cost $406 million. Tenet reaffirmed its FY 2022 Adjusted EBITDA outlook at $3.375 billion to $3.575 billion, despite a significant debt refinancing, reducing future annual interest payments by $61 million.
- Adjusted EBITDA rose to $843 million in Q2 2022, indicating resilience amidst challenges.
- Acquisition of USPI's remaining 5% ownership enhances Tenet's growth potential.
- Future annual cash interest payments reduced by $61 million through successful debt refinancing.
- Net income declined to $38 million from $120 million year-over-year.
- Diluted EPS dropped to $0.35 from $1.11 in Q2 2021.
- Cybersecurity incident adversely affected adjusted admissions, decreasing by 5.3%.
-
Net income from continuing operations available to common shareholders in Q2’22 of
versus$38 million in Q2’21$120 million -
Consolidated Adjusted EBITDA in Q2’22 of
versus$843 million in Q2’21$834 million - Q2'22 USPI Adjusted EBITDA grew 15.3 percent over Q2'21 excluding grant income; Same-facility system-wide ambulatory surgical cases decreased 0.9 percent versus Q2’21 due to the pandemic
-
Diluted earnings per share from continuing operations available to common shareholders in Q2’22 of
compared to$0.35 in Q2’21; Adjusted diluted earnings per share from continuing operations of$1.11 in Q2’22 compared to$1.50 in Q2’21$1.59 - The disruptive cybersecurity incident contributed to same-hospital adjusted admissions for Q2’22 decreasing 5.3 percent versus Q2’21
-
Effective
June 30, 2022 , Tenet now owns100% of USPI’s voting stock, having acquired the remaining5% ownership interest for$406 million -
Refinanced
~ of$1.75 billion 6.75% senior unsecured notes due 2023 with new6.125% senior secured notes due 2030; the Company has no significant debt maturities untilJuly 2024 -
FY 2022 Adjusted EBITDA Outlook reaffirmed at
to$3.37 5 billion$3.57 5 billion
($ in millions, except per share results) |
Q2’22 |
Q2’21 |
YTD Q2’22 |
YTD Q2’21 |
Net income available to Tenet common shareholders from continuing operations |
|
|
|
|
Net income available to Tenet common shareholders from continuing operations per diluted share |
|
|
|
|
Adjusted EBITDA excluding grant income |
|
|
|
|
Adjusted EBITDA including grant income |
|
|
|
|
Adjusted diluted earnings per share from continuing operations |
|
|
|
|
The table above as well as tables and discussions throughout this earnings release include certain financial measures that are not in accordance with accounting principles generally accepted in |
“We had another strong quarter and are reaffirming our 2022 Adjusted EBITDA Outlook,” said
COVID-19 Pandemic (COVID)
The Company continues to treat COVID patients and effectively manage the operational and financial impact of the pandemic on its operations. COVID admissions were 3 percent of total admissions in Q2’22 compared to 12 percent of total admissions in Q1’22.
Results from Continuing Operations Available to Tenet Common Shareholders
-
Net income from continuing operations available to the Company’s common shareholders in Q2’22 was
, or$38 million per diluted share, versus$0.35 , or$120 million per diluted share, in Q2’21.$1.11 -
For YTD Q2’22, net income from continuing operations available to the Company’s common shareholders was
, or$177 million per diluted share, compared to$1.63 , or$217 million per diluted share, for YTD Q2’21.$2.00
Adjusted Net Income from Continuing Operations Available to Tenet Common Shareholders
Reconciliations of net income available to Tenet common shareholders to Adjusted net income from continuing operations available to Tenet common shareholders are contained in Table #1 at the end of this release.
-
Tenet’s Q2’22 Adjusted net income from continuing operations available to its common shareholders was
, or$163 million per diluted share, compared to$1.50 , or$173 million per diluted share, in Q2’21.$1.59 -
Tenet’s YTD Q2’22 Adjusted net income from continuing operations available to its common shareholders was
, or$376 million per diluted share, compared to$3.38 , or$313 million per diluted share, in YTD Q2’21.$2.89 -
The change in the interest expense limitation regulations beginning in 2022 resulted in approximately
of additional income tax expense in Q2’22 and$20 million YTD Q2’22, or$39 million and$0.18 per diluted share, respectively, compared to the corresponding 2021 periods.$0.34
Adjusted EBITDA
Reconciliations of net income available to Tenet common shareholders to Adjusted EBITDA are contained in Table #2 at the end of this release.
-
Adjusted EBITDA in Q2’22 was
compared to$843 million in Q2’21.$834 million -
For YTD Q2’22, Adjusted EBITDA was
compared to$1.73 1 billion in YTD Q2’21.$1.61 1 billion
Cybersecurity Incident
-
In
April 2022 , Tenet experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations. During this time, the Company's hospitals remained operational and continued to deliver patient care safely and effectively, utilizing well-established back‑up processes. The Company immediately suspended user access to impacted information technology applications, executed extensive cybersecurity protection protocols, and took steps to restrict further unauthorized activity. -
Tenet has fully restored impacted information technology operations. The Company estimates that this incident had an unfavorable impact of approximately
to Adjusted EBITDA during Q2’22. The Company has insurance coverage and filed a claim that is within its policy limits, which is ongoing.$100 million of insurance proceeds were received during Q2’22.$5 million
Acquires remainder of USPI
-
On
June 30, 2022 , the Company acquired Baylor University Medical Center’s entire5% ownership interest in our USPI business for . The Company now owns$406 million 100% of the voting stock of USPI. Under the terms of the transaction, Tenet will pay approximately per month over the next three years on an interest-free basis. The first payment was made in Q2’22.$11 million
Financing Activities
-
In
June 2022 , the Company completed a private placement of in aggregate principal amount of newly issued 6.125 percent senior secured first lien notes maturing in 2030. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance the redemption of all$2.00 0 billion aggregate principal amount then outstanding of its 6.75 percent senior unsecured notes due 2023.$1.74 8 billion -
In Q1’22, the Company retired
aggregate principal amount of its 7.50 percent senior secured notes due in 2025, for a total redemption price of approximately$700 million , using available cash on hand. In the first half of 2022, the Company purchased approximately$730 million aggregate principal amount of its 6.75 percent senior unsecured notes due in 2023 on the open market for approximately$124 million using available cash on hand ($129 million of which was purchased in Q1’22). In conjunction with these transactions, the Company’s future annual cash interest payments will be reduced by$103 million .$61 million
Ambulatory Care (Ambulatory) Segment Results
Tenet’s Ambulatory business segment is comprised of the operations of
Ambulatory segment results ($ in millions) |
Q2’22 |
Q2’21 |
YTD Q2’22 |
YTD Q2’21 |
Revenues |
|
|
|
|
Net operating revenues |
|
|
|
|
Grant income excluding amount in equity earnings |
|
|
|
|
Grant income in equity earnings |
$— |
|
$— |
|
Same-facility system-wide net patient service revenues (a) |
|
|
|
|
Volume Changes versus the Prior-Year Period |
|
|
|
|
Same-facility system-wide surgical cases (a) |
(0.9) % |
68.2 % |
3.3 % |
29.1 % |
Same-facility system-wide surgical cases on same-business day basis (a) |
(0.9) % |
68.2 % |
2.4 % |
30.1 % |
Adjusted EBITDA, Margins and Noncontrolling Interest (NCI) |
|
|
|
|
Adjusted EBITDA excluding grant income |
|
|
|
|
Adjusted EBITDA including grant income |
|
|
|
|
Adjusted EBITDA margin excluding grant income |
41.1 % |
41.4 % |
39.6 % |
39.6 % |
Adjusted EBITDA margin including grant income |
41.4 % |
44.4 % |
39.8 % |
42.1 % |
Adjusted EBITDA less facility-level NCI excluding grant income |
|
|
|
|
Adjusted EBITDA less facility-level NCI |
|
|
|
|
Adjusted EBITDA less total NCI excluding grant income |
|
|
|
|
Adjusted EBITDA less total NCI |
|
|
|
|
(a) |
Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities. |
Revenues and Volumes
-
The Ambulatory segment produced net operating revenues of
in Q2’22, an increase of 16.1 percent compared to$771 million in Q2’21. This increase primarily related to service line growth and additional revenues associated with the$664 million SurgCenter Development (SCD) acquisition completed inDecember 2021 and improved pricing yield, partially offset by the absence of revenues from USPI’s urgent care centers, which were sold in the second quarter of 2021. - Surgical business same-facility system-wide net operating revenues increased 2.8 percent in Q2’22 compared to Q2’21, with cases down 0.9 percent and net revenue per case up 3.7 percent.
Adjusted EBITDA
-
Ambulatory segment Adjusted EBITDA was
in Q2’22 ($319 million excluding$317 million of grant income) compared to$2 million in Q2’21 ($295 million excluding$275 million of grant income), driven by the SCD acquisition, as well as new service line growth and improved pricing yield.$20 million - Adjusted EBITDA margin for the Ambulatory segment was 41.4 percent in Q2’22 (41.1 percent excluding grant income) compared to 44.4 percent in Q2’21 (41.4 percent excluding grant income).
-
Adjusted EBITDA less facility-level NCI in Q2’22 was
($210 million excluding grant income) compared to$209 million in Q2’21 ($187 million excluding grant income).$176 million
Hospital Operations and Other (Hospital) Segment Results
Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. Effective
Hospital segment results ($ in millions) |
Q2’22 |
Q2’21 |
YTD Q2’22 |
YTD Q2’21 |
Revenues |
|
|
|
|
Net operating revenues (prior to inter-segment eliminations) |
|
|
|
|
Grant income |
|
|
|
|
Same-hospital net patient service revenues (b) |
|
|
|
|
Same-Hospital Volume Changes versus the Prior-Year Period (b) |
|
|
|
|
Admissions |
(8.1) % |
13.8 % |
(6.4) % |
0.4 % |
Adjusted admissions (c) |
(5.3) % |
23.6 % |
(3.5) % |
2.6 % |
Outpatient visits (including outpatient ER visits) |
(10.0) % |
71.1 % |
(4.7) % |
19.7 % |
Emergency Room visits (inpatient and outpatient) |
3.8 % |
35.2 % |
8.5 % |
(2.1) % |
Hospital surgeries |
(8.0) % |
36.5 % |
(4.3) % |
13.1 % |
Adjusted EBITDA |
|
|
|
|
Adjusted EBITDA excluding grant income |
|
|
|
|
Adjusted EBITDA including grant income |
|
|
|
|
Adjusted EBITDA margin |
|
|
|
|
Adjusted EBITDA margin excluding grant income |
9.3 % |
10.9 % |
11.4 % |
10.6 % |
Adjusted EBITDA margin including grant income |
11.8 % |
11.0 % |
12.7 % |
11.0 % |
(b) |
Same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from |
|
(c) |
Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues. |
Revenues and Volumes
-
Net operating revenues (which exclude grant income) in the Hospital segment were
in Q2’22, a decline of 11.0 percent from$3.64 5 billion in Q2’21. The decrease in revenues was primarily due to the sale of the Company’s$4.09 5 billionMiami -area hospitals in Q3’21 and the unfavorable impact of the cybersecurity incident, partially offset by improved pricing yield. - Same-hospital net patient service revenue per adjusted admission decreased 0.2 percent year-over-year for Q2’22 primarily due to the unfavorable impact of the cybersecurity incident, partially offset by improved pricing yield.
Adjusted EBITDA
-
Adjusted EBITDA in the segment was
in Q2’22 ($431 million excluding$339 million of grant income) compared to$92 million in Q2’21 ($449 million excluding$445 million of grant income).$4 million -
Adjusted EBITDA in Q2’22 included an approximate
unfavorable impact related to the cybersecurity incident.$100 million - The Adjusted EBITDA margin excluding grant income was 9.3 percent in Q2’22 compared to 10.9 percent in Q2’21 reflecting the adverse impact from the cybersecurity incident, higher contract labor rates and premium pay due to the pandemic, partially offset by continued strength in patient acuity due to the Company's focus on growing higher acuity services, improved pricing yield and cost efficiency actions.
Conifer Segment Results
Tenet’s Conifer business segment provides comprehensive end-to-end and focused-point business process services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions to hospitals, health systems, physician practices, employers and other clients.
Conifer segment results ($ in millions) |
Q2’22 |
Q2’21 |
YTD Q2’22 |
YTD Q2’21 |
Net operating revenues |
|
|
|
|
Adjusted EBITDA |
|
|
|
|
Adjusted EBITDA margin |
27.9 % |
28.2 % |
28.2 % |
28.0 % |
Revenues
Conifer segment revenues in Q2’22 were
Adjusted EBITDA
Conifer generated
Balance Sheet, Cash Flows and Liquidity
Balance Sheet Highlights
($ in millions) |
|
|
|
Cash and cash equivalents |
|
|
|
Accounts receivable days outstanding |
59.8 |
58.9 |
57.0 |
Line-of-credit borrowings outstanding |
— |
— |
— |
Ratio of net debt plus Medicare advances liability to Adjusted EBITDA (d) |
3.92 |
3.93 |
4.07 |
(d) | Net debt is total debt less cash and cash equivalents |
-
Cash and cash equivalents at
June 30, 2022 were lower than$1.01 3 billionDecember 31, 2021 primarily due to the Company’s early retirement of of debt.$824 million -
In the year ended
December 31, 2020 (FY 2020), the Company received approximately of Medicare advance payments from CMS related to the pandemic. Approximately$1.5 billion of the Medicare advances were repaid in the YTD Q2’22 period by the Company, and approximately$475 million of these advances were repaid by the Company during the year ended$616 million December 31, 2021 . Repayment terms for the Medicare advance payments began inApril 2021 (12 months from the Company’s receipt of the advance payments inApril 2020 ). An annual interest rate of 4.0 percent will be assessed on any outstanding balances 29 months from the initial advance. The Company began repaying these advance payments inApril 2021 and expects to substantially repay the advances by the end of Q3'22. -
The Company had no outstanding borrowings on its
line of credit as of$1.5 billion June 30, 2022 . -
The Company’s ratio of net debt plus the Medicare advances liability to Adjusted EBITDA was 3.92x at
June 30, 2022 compared to 3.93x atMarch 31, 2022 and 4.07x atDecember 31, 2021 . -
Accounts receivable days outstanding increased to 59.8 days at
June 30, 2022 compared to 57.0 days atDecember 31, 2021 . This change is due in part to the cybersecurity incident and the approval of Texas’ Medicaid supplemental funding programs by CMS at the end ofMarch 2022 , which resulted in the Company recognizing revenue beginning inMarch 2022 that has not been fully collected yet since the program was just recently approved.
Cash flows and liquidity
Reconciliations of net cash provided by operating activities to both Free Cash Flow and Adjusted Free Cash Flow are contained in Table #3 at the end of this release.
($ in millions) |
Q2’22 |
Q2’21 |
YTD Q2’22 |
YTD Q2’21 |
Net cash provided by operating activities |
|
|
|
|
Capital expenditures |
( |
( |
( |
( |
Free cash flow |
( |
|
|
|
Adjusted free cash flow |
|
|
|
|
Net cash used in investing activities |
( |
( |
( |
( |
Net cash used in financing activities |
( |
( |
( |
( |
-
The Company produced free cash flow of
in Q2’22 ($(33) million excluding$248 million of repayments in Q2’22 associated with Medicare advances). There were$281 million repayments of Medicare advances in Q2’21.$152 million -
The Company produced free cash flow of
in YTD Q2’22 ($40 million excluding$515 million of repayments in YTD Q2’22 associated with Medicare advances). There were no repayments of Medicare advances in Q1’21 and$475 million repayments of Medicare advances in Q2’21.$152 million -
Also, free cash flow in YTD Q2’22 included
of pandemic-related grant receipts compared to$104 million in YTD Q2’21.$36 million
Company Outlook
-
Reconciliations of Outlook net income available to Tenet common shareholders to Outlook Adjusted EBITDA for the year ending
December 31, 2022 (FY 2022) and the quarter endingSeptember 30, 2022 (Q3’22) are contained in Table #4 at the end of this release. - Reconciliations of Outlook net income available to Tenet common shareholders to Outlook Adjusted net income from continuing operations to common shareholders for FY 2022 and Q3’22 are contained in Table #5 at the end of this release.
- Reconciliations of Outlook net cash provided by operating activities to Outlook free cash flow and Outlook Adjusted free cash flow from continuing operations for FY 2022 are contained in Table #6 at the end of this release.
Tenet’s Outlook for FY 2022 (consolidated and by segment) and Q3’22 follows:
CONSOLIDATED ($ in millions except per share amounts) |
FY 2022 Outlook |
Q3’22 Outlook |
Net operating revenues |
|
|
Income from continuing operations available to Tenet common stockholders |
|
|
Adjusted EBITDA |
|
|
Adjusted EBITDA margin |
|
|
Diluted income per common share from continuing operations |
|
|
Adjusted net income from continuing operations |
|
|
Adjusted diluted earnings per share from continuing operations |
|
|
Equity in earnings of unconsolidated affiliates |
|
|
Depreciation and amortization |
|
|
Interest expense |
|
|
Net income available to NCI |
|
|
Weighted average diluted common shares |
~112 million |
~110 million |
NCI cash distributions |
|
|
Effective tax rate (e) |
~ |
|
Net cash provided by operating activities |
|
|
Adjusted net cash provided by operating activities |
|
|
Capital expenditures |
|
|
Free cash flow |
|
|
Free cash flow excluding repayments of Medicare Advance Payments and Deferred Payroll Tax Payments |
|
|
Adjusted free cash flow – continuing operations |
|
|
Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advance Payments and Deferred Payroll Tax Payments |
|
|
(e) |
The effective tax rate is calculated as income tax expense divided by the adjusted pretax income. Income tax expense is calculated by multiplying |
Ambulatory Segment ($ in millions) |
FY 2022 Outlook |
Net operating revenues |
|
Adjusted EBITDA |
|
Total NCI (Facility level and |
|
Adjusted EBITDA less total NCI |
|
Changes versus prior year (f): |
|
Surgical cases volumes |
Up |
Net revenues per surgical case |
Up |
Hospital Segment ($ in millions) |
FY 2022 Outlook |
Net operating revenues (prior to inter-segment eliminations) |
|
Adjusted EBITDA |
|
NCI |
|
Changes versus prior year (f): |
|
Inpatient admissions |
(6)% to (4)% |
Adjusted admissions |
(4)% to (2)% |
Conifer Segment ($ in millions) |
FY 2022 Outlook |
Net operating revenues |
|
Adjusted EBITDA |
|
NCI |
|
(f) |
Same-hospital basis for hospital statistics; USPI surgical cases on a same-facility system-wide basis |
Management’s Webcast Discussion of Results
Tenet management will discuss the Company’s Q2’22 results in a webcast scheduled for
The slide presentation associated with the webcast referenced above, a copy of this earnings press release and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended
About
Non-GAAP Financial Measures
- Adjusted EBITDA, a non-GAAP measure, is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
- Adjusted diluted earnings (loss) per share from continuing operations, a non-GAAP measure, is defined by the Company as Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
- Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, a non-GAAP measure, is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
- Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment for continuing operations.
- Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments, a non-GAAP measure, is defined by the Company as (1) Free Cash Flow plus (2) repayments of Medicare Advances and Deferred Payroll Tax Payments.
- Adjusted Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities from continuing operations, less (2) purchases of property and equipment from continuing operations.
- Adjusted Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments, a non-GAAP measure, is defined by the Company as (1) Adjusted Free Cash Flow plus (2) repayments of Medicare Advances and Deferred Payroll Tax Payments.
- Adjusted net cash provided by (used in) operating activities, a non-GAAP measure, is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.
The Company believes the foregoing non-GAAP measures are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The
The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.
The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow, and Free Cash Flow and Adjusted Free Cash Flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.
These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.
Financial Statements and Reconciliations Q2’22 Earnings Release |
|
Table of Contents |
|
Description |
Page |
Consolidated Statements of Operations |
14 |
Consolidated Balance Sheets |
16 |
Consolidated Statements of Cash Flow |
17 |
Segment Reporting |
18 |
Table #1 - Reconciliations of Net Income to Adjusted Net Income |
19 |
Table #2 - Reconciliations of Net Income to Adjusted EBITDA |
20 |
Table #3 - Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow |
21 |
Table #4 - Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA |
22 |
Table #5 - Reconciliations of Outlook Net Income to Outlook Adjusted Net Income |
23 |
Table #6 - Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow |
24 |
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||
(Dollars in millions except per share amounts) |
|
Three Months Ended |
|||||||||||||||
|
|
2022 |
|
% |
|
2021 |
|
% |
|
Change |
|||||||
Net operating revenues |
|
$ |
4,638 |
|
|
100.0 |
% |
|
$ |
4,954 |
|
|
100.0 |
% |
|
(6.4 |
) % |
Grant income |
|
|
94 |
|
|
2.0 |
% |
|
|
19 |
|
|
0.4 |
% |
|
394.7 |
% |
Equity in earnings of unconsolidated affiliates |
|
|
54 |
|
|
1.2 |
% |
|
|
54 |
|
|
1.1 |
% |
|
0.0 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|||||||
Salaries, wages and benefits |
|
|
2,126 |
|
|
45.8 |
% |
|
|
2,280 |
|
|
46.0 |
% |
|
(6.8 |
) % |
Supplies |
|
|
811 |
|
|
17.5 |
% |
|
|
859 |
|
|
17.4 |
% |
|
(5.6 |
) % |
Other operating expenses, net |
|
|
1,006 |
|
|
21.7 |
% |
|
|
1,054 |
|
|
21.3 |
% |
|
(4.6 |
) % |
Depreciation and amortization |
|
|
216 |
|
|
4.7 |
% |
|
|
221 |
|
|
4.5 |
% |
|
|
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
57 |
|
|
1.2 |
% |
|
|
20 |
|
|
0.4 |
% |
|
|
|
Litigation and investigation costs |
|
|
18 |
|
|
0.4 |
% |
|
|
22 |
|
|
0.4 |
% |
|
|
|
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
(1 |
) |
|
— |
% |
|
|
(15 |
) |
|
(0.3 |
) % |
|
|
|
Operating income |
|
|
553 |
|
|
11.9 |
% |
|
|
586 |
|
|
11.8 |
% |
|
|
|
Interest expense |
|
|
(222 |
) |
|
|
|
|
(235 |
) |
|
|
|
|
|||
Other non-operating expense, net |
|
|
— |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Loss from early extinguishment of debt |
|
|
(66 |
) |
|
|
|
|
(31 |
) |
|
|
|
|
|||
Income from continuing operations, before income taxes |
|
|
265 |
|
|
|
|
|
319 |
|
|
|
|
|
|||
Income tax expense |
|
|
(86 |
) |
|
|
|
|
(61 |
) |
|
|
|
|
|||
Income from continuing operations, before discontinued operations |
|
|
179 |
|
|
|
|
|
258 |
|
|
|
|
|
|||
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|||||||
Loss from operations |
|
|
— |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Loss from discontinued operations |
|
|
— |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Net income |
|
|
179 |
|
|
|
|
|
257 |
|
|
|
|
|
|||
Less: Net income available to noncontrolling interests |
|
|
141 |
|
|
|
|
|
138 |
|
|
|
|
|
|||
Net income available to |
|
$ |
38 |
|
|
|
|
$ |
119 |
|
|
|
|
|
|||
Amounts available to |
|
|
|
|
|
|
|
|
|
|
|||||||
Income from continuing operations, net of tax |
|
$ |
38 |
|
|
|
|
$ |
120 |
|
|
|
|
|
|||
Loss from discontinued operations, net of tax |
|
|
— |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Net income available to |
|
$ |
38 |
|
|
|
|
$ |
119 |
|
|
|
|
|
|||
Earnings (loss) per share available (attributable) to |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
|
|
|
|
|
|
|
|
|||||||
Continuing operations |
|
$ |
0.35 |
|
|
|
|
$ |
1.12 |
|
|
|
|
|
|||
Discontinued operations |
|
|
— |
|
|
|
|
|
(0.01 |
) |
|
|
|
|
|||
|
|
$ |
0.35 |
|
|
|
|
$ |
1.11 |
|
|
|
|
|
|||
Diluted |
|
|
|
|
|
|
|
|
|
|
|||||||
Continuing operations |
|
$ |
0.35 |
|
|
|
|
$ |
1.11 |
|
|
|
|
|
|||
Discontinued operations |
|
|
— |
|
|
|
|
|
(0.01 |
) |
|
|
|
|
|||
|
|
$ |
0.35 |
|
|
|
|
$ |
1.10 |
|
|
|
|
|
|||
Weighted average shares and dilutive securities outstanding (in thousands): |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
107,790 |
|
|
|
|
|
106,822 |
|
|
|
|
|
|||
Diluted |
|
|
108,750 |
|
|
|
|
|
108,569 |
|
|
|
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||
(Dollars in millions except per share amounts) |
|
Six Months Ended |
|||||||||||||||
|
|
2022 |
|
% |
|
2021 |
|
% |
|
Change |
|||||||
Net operating revenues |
|
$ |
9,383 |
|
|
100.0 |
% |
|
$ |
9,735 |
|
|
100.0 |
% |
|
(3.6 |
) % |
Grant income |
|
|
100 |
|
|
1.1 |
% |
|
|
50 |
|
|
0.5 |
% |
|
100.0 |
% |
Equity in earnings of unconsolidated affiliates |
|
|
100 |
|
|
1.1 |
% |
|
|
96 |
|
|
1.0 |
% |
|
4.2 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|||||||
Salaries, wages and benefits |
|
|
4,308 |
|
|
45.9 |
% |
|
|
4,481 |
|
|
46.0 |
% |
|
(3.9 |
) % |
Supplies |
|
|
1,596 |
|
|
17.0 |
% |
|
|
1,663 |
|
|
17.1 |
% |
|
(4.0 |
) % |
Other operating expenses, net |
|
|
1,948 |
|
|
20.8 |
% |
|
|
2,126 |
|
|
21.8 |
% |
|
(8.4 |
) % |
Depreciation and amortization |
|
|
419 |
|
|
4.5 |
% |
|
|
445 |
|
|
4.6 |
% |
|
|
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
73 |
|
|
0.8 |
% |
|
|
40 |
|
|
0.4 |
% |
|
|
|
Litigation and investigation costs |
|
|
38 |
|
|
0.4 |
% |
|
|
35 |
|
|
0.4 |
% |
|
|
|
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
— |
|
|
— |
% |
|
|
(15 |
) |
|
(0.2 |
) % |
|
|
|
Operating income |
|
|
1,201 |
|
|
12.8 |
% |
|
|
1,106 |
|
|
11.4 |
% |
|
|
|
Interest expense |
|
|
(449 |
) |
|
|
|
|
(475 |
) |
|
|
|
|
|||
Other non-operating income, net |
|
|
— |
|
|
|
|
|
9 |
|
|
|
|
|
|||
Loss from early extinguishment of debt |
|
|
(109 |
) |
|
|
|
|
(54 |
) |
|
|
|
|
|||
Income from continuing operations, before income taxes |
|
|
643 |
|
|
|
|
|
586 |
|
|
|
|
|
|||
Income tax expense |
|
|
(185 |
) |
|
|
|
|
(106 |
) |
|
|
|
|
|||
Income from continuing operations, before discontinued operations |
|
|
458 |
|
|
|
|
|
480 |
|
|
|
|
|
|||
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|||||||
Income (loss) from operations |
|
|
1 |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Income (loss) from discontinued operations |
|
|
1 |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Net income |
|
|
459 |
|
|
|
|
|
479 |
|
|
|
|
|
|||
Less: Net income available to noncontrolling interests |
|
|
281 |
|
|
|
|
|
263 |
|
|
|
|
|
|||
Net income available to |
|
$ |
178 |
|
|
|
|
$ |
216 |
|
|
|
|
|
|||
Amounts available (attributable) to |
|
|
|
|
|
|
|
|
|
|
|||||||
Income from continuing operations, net of tax |
|
$ |
177 |
|
|
|
|
$ |
217 |
|
|
|
|
|
|||
Income (loss) from discontinued operations, net of tax |
|
|
1 |
|
|
|
|
|
(1 |
) |
|
|
|
|
|||
Net income available to |
|
$ |
178 |
|
|
|
|
$ |
216 |
|
|
|
|
|
|||
Earnings (loss) per share available (attributable) to |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
|
|
|
|
|
|
|
|
|||||||
Continuing operations |
|
$ |
1.64 |
|
|
|
|
$ |
2.04 |
|
|
|
|
|
|||
Discontinued operations |
|
|
0.01 |
|
|
|
|
|
(0.01 |
) |
|
|
|
|
|||
|
|
$ |
1.65 |
|
|
|
|
$ |
2.03 |
|
|
|
|
|
|||
Diluted |
|
|
|
|
|
|
|
|
|
|
|||||||
Continuing operations |
|
$ |
1.63 |
|
|
|
|
$ |
2.00 |
|
|
|
|
|
|||
Discontinued operations |
|
|
0.01 |
|
|
|
|
|
(0.01 |
) |
|
|
|
|
|||
|
|
$ |
1.64 |
|
|
|
|
$ |
1.99 |
|
|
|
|
|
|||
Weighted average shares and dilutive securities outstanding (in thousands): |
|
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
107,636 |
|
|
|
|
|
106,566 |
|
|
|
|
|
|||
Diluted |
|
|
114,054 |
|
|
|
|
|
108,317 |
|
|
|
|
|
CONSOLIDATED BALANCE SHEETS (Unaudited) |
||||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
(Dollars in millions) |
|
2022 |
|
2021 |
||||
ASSETS |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
1,351 |
|
|
$ |
2,364 |
|
Accounts receivable |
|
|
2,840 |
|
|
|
2,770 |
|
Inventories of supplies, at cost |
|
|
387 |
|
|
|
384 |
|
Income tax receivable |
|
|
18 |
|
|
|
— |
|
Other current assets |
|
|
1,468 |
|
|
|
1,557 |
|
Total current assets |
|
|
6,064 |
|
|
|
7,075 |
|
Investments and other assets |
|
|
3,297 |
|
|
|
3,254 |
|
Deferred income taxes |
|
|
60 |
|
|
|
65 |
|
Property and equipment, at cost, less accumulated depreciation and amortization |
|
|
6,259 |
|
|
|
6,427 |
|
|
|
|
9,479 |
|
|
|
9,261 |
|
Other intangible assets, at cost, less accumulated amortization |
|
|
1,462 |
|
|
|
1,497 |
|
Total assets |
|
$ |
26,621 |
|
|
$ |
27,579 |
|
|
|
|
|
|
||||
LIABILITIES AND EQUITY |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Current portion of long-term debt |
|
$ |
125 |
|
|
$ |
135 |
|
Accounts payable |
|
|
1,083 |
|
|
|
1,300 |
|
Accrued compensation and benefits |
|
|
811 |
|
|
|
896 |
|
Professional and general liability reserves |
|
|
272 |
|
|
|
254 |
|
Accrued interest payable |
|
|
221 |
|
|
|
203 |
|
Contract liabilities |
|
|
474 |
|
|
|
959 |
|
Other current liabilities |
|
|
1,382 |
|
|
|
1,362 |
|
Total current liabilities |
|
|
4,368 |
|
|
|
5,109 |
|
Long-term debt, net of current portion |
|
|
14,947 |
|
|
|
15,511 |
|
Professional and general liability reserves |
|
|
789 |
|
|
|
791 |
|
Defined benefit plan obligations |
|
|
407 |
|
|
|
421 |
|
Deferred income taxes |
|
|
161 |
|
|
|
36 |
|
Contract liabilities - long-term |
|
|
14 |
|
|
|
15 |
|
Other long-term liabilities |
|
|
1,824 |
|
|
|
1,439 |
|
Total liabilities |
|
|
22,510 |
|
|
|
23,322 |
|
Commitments and contingencies |
|
|
|
|
||||
Redeemable noncontrolling interests in equity of consolidated subsidiaries |
|
|
1,997 |
|
|
|
2,203 |
|
Equity: |
|
|
|
|
||||
Shareholders’ equity: |
|
|
|
|
||||
Common stock |
|
|
8 |
|
|
|
8 |
|
Additional paid-in capital |
|
|
4,756 |
|
|
|
4,877 |
|
Accumulated other comprehensive loss |
|
|
(231 |
) |
|
|
(233 |
) |
Accumulated deficit |
|
|
(1,036 |
) |
|
|
(1,214 |
) |
Common stock in treasury, at cost |
|
|
(2,410 |
) |
|
|
(2,410 |
) |
Total shareholders’ equity |
|
|
1,087 |
|
|
|
1,028 |
|
Noncontrolling interests |
|
|
1,027 |
|
|
|
1,026 |
|
Total equity |
|
|
2,114 |
|
|
|
2,054 |
|
Total liabilities and equity |
|
$ |
26,621 |
|
|
$ |
27,579 |
|
CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) |
||||||||
|
|
Six Months Ended |
||||||
(Dollars in millions) |
|
|
||||||
|
|
2022 |
|
2021 |
||||
Net income |
|
$ |
459 |
|
|
$ |
479 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
419 |
|
|
|
445 |
|
Deferred income tax expense |
|
|
132 |
|
|
|
48 |
|
Stock-based compensation expense |
|
|
34 |
|
|
|
30 |
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
73 |
|
|
|
40 |
|
Litigation and investigation costs |
|
|
38 |
|
|
|
35 |
|
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
— |
|
|
|
(15 |
) |
Loss from early extinguishment of debt |
|
|
109 |
|
|
|
54 |
|
Equity in earnings of unconsolidated affiliates, net of distributions received |
|
|
18 |
|
|
|
10 |
|
Amortization of debt discount and debt issuance costs |
|
|
15 |
|
|
|
17 |
|
Pre-tax (income) loss from discontinued operations |
|
|
(1 |
) |
|
|
1 |
|
Other items, net |
|
|
(59 |
) |
|
|
(22 |
) |
Changes in cash from operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable |
|
|
(74 |
) |
|
|
(101 |
) |
Inventories and other current assets |
|
|
173 |
|
|
|
56 |
|
Income taxes |
|
|
(86 |
) |
|
|
25 |
|
Accounts payable, accrued expenses, contract liabilities and other current liabilities |
|
|
(764 |
) |
|
|
(232 |
) |
Other long-term liabilities |
|
|
(41 |
) |
|
|
(6 |
) |
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(98 |
) |
|
|
(85 |
) |
Net cash provided by operating activities |
|
|
347 |
|
|
|
779 |
|
Cash flows from investing activities: |
|
|
|
|
||||
Purchases of property and equipment |
|
|
(307 |
) |
|
|
(243 |
) |
Purchases of businesses or joint venture interests, net of cash acquired |
|
|
(66 |
) |
|
|
(64 |
) |
Proceeds from sales of facilities and other assets |
|
|
209 |
|
|
|
124 |
|
Proceeds from sales of marketable securities, long-term investments and other assets |
|
|
9 |
|
|
|
18 |
|
Purchases of marketable securities and equity investments |
|
|
(41 |
) |
|
|
(19 |
) |
Other items, net |
|
|
(4 |
) |
|
|
(11 |
) |
Net cash used in investing activities |
|
|
(200 |
) |
|
|
(195 |
) |
Cash flows from financing activities: |
|
|
|
|
||||
Repayments of other borrowings |
|
|
(2,744 |
) |
|
|
(2,012 |
) |
Proceeds from other borrowings |
|
|
2,013 |
|
|
|
1,409 |
|
Debt issuance costs |
|
|
(24 |
) |
|
|
(15 |
) |
Distributions paid to noncontrolling interests |
|
|
(310 |
) |
|
|
(212 |
) |
Proceeds from sale of noncontrolling interests |
|
|
9 |
|
|
|
12 |
|
Purchases of noncontrolling interests |
|
|
(29 |
) |
|
|
(5 |
) |
Medicare advances and grants received by unconsolidated affiliates, net of recoupment |
|
|
— |
|
|
|
6 |
|
Other items, net |
|
|
(75 |
) |
|
|
(19 |
) |
Net cash used in financing activities |
|
|
(1,160 |
) |
|
|
(836 |
) |
Net decrease in cash and cash equivalents |
|
|
(1,013 |
) |
|
|
(252 |
) |
Cash and cash equivalents at beginning of period |
|
|
2,364 |
|
|
|
2,446 |
|
Cash and cash equivalents at end of period |
|
$ |
1,351 |
|
|
$ |
2,194 |
|
Supplemental disclosures: |
|
|
|
|
||||
Interest paid, net of capitalized interest |
|
$ |
(416 |
) |
|
$ |
(486 |
) |
Income tax payments, net |
|
$ |
(140 |
) |
|
$ |
(34 |
) |
SEGMENT REPORTING (Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
(Dollars in millions) |
|
|
|
|
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Net operating revenues (1) : |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
771 |
|
|
$ |
664 |
|
|
$ |
1,509 |
|
|
$ |
1,310 |
|
Hospital Operations and other (prior to inter-segment eliminations) |
|
|
3,645 |
|
|
|
4,095 |
|
|
|
7,443 |
|
|
|
8,042 |
|
Conifer |
|
|
|
|
|
|
|
|
||||||||
Tenet |
|
|
111 |
|
|
|
124 |
|
|
|
226 |
|
|
|
246 |
|
Other clients |
|
|
222 |
|
|
|
195 |
|
|
|
431 |
|
|
|
383 |
|
Total Conifer revenues |
|
|
333 |
|
|
|
319 |
|
|
|
657 |
|
|
|
629 |
|
Inter-segment eliminations |
|
|
(111 |
) |
|
|
(124 |
) |
|
|
(226 |
) |
|
|
(246 |
) |
Total |
|
$ |
4,638 |
|
|
$ |
4,954 |
|
|
$ |
9,383 |
|
|
$ |
9,735 |
|
|
|
|
|
|
|
|
|
|
||||||||
Equity in earnings of unconsolidated affiliates: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
52 |
|
|
$ |
49 |
|
|
$ |
94 |
|
|
$ |
87 |
|
Hospital Operations and other |
|
|
2 |
|
|
|
5 |
|
|
|
6 |
|
|
|
9 |
|
Total |
|
$ |
54 |
|
|
$ |
54 |
|
|
$ |
100 |
|
|
$ |
96 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA (including grant income): |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
319 |
|
|
$ |
295 |
|
|
$ |
601 |
|
|
$ |
552 |
|
Hospital Operations and other |
|
|
431 |
|
|
|
449 |
|
|
|
945 |
|
|
|
883 |
|
Conifer |
|
|
93 |
|
|
|
90 |
|
|
|
185 |
|
|
|
176 |
|
Total |
|
$ |
843 |
|
|
$ |
834 |
|
|
$ |
1,731 |
|
|
$ |
1,611 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA margins (including grant income): |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
|
41.4 |
% |
|
|
44.4 |
% |
|
|
39.8 |
% |
|
|
42.1 |
% |
Hospital Operations and other |
|
|
11.8 |
% |
|
|
11.0 |
% |
|
|
12.7 |
% |
|
|
11.0 |
% |
Conifer |
|
|
27.9 |
% |
|
|
28.2 |
% |
|
|
28.2 |
% |
|
|
28.0 |
% |
Total |
|
|
18.2 |
% |
|
|
16.8 |
% |
|
|
18.4 |
% |
|
|
16.5 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA margins (excluding grant income): |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
|
41.1 |
% |
|
|
41.4 |
% |
|
|
39.6 |
% |
|
|
39.6 |
% |
Hospital Operations and other |
|
|
9.3 |
% |
|
|
10.9 |
% |
|
|
11.4 |
% |
|
|
10.6 |
% |
Conifer |
|
|
27.9 |
% |
|
|
28.2 |
% |
|
|
28.2 |
% |
|
|
28.0 |
% |
Total |
|
|
16.1 |
% |
|
|
16.4 |
% |
|
|
17.4 |
% |
|
|
15.9 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Capital expenditures: |
|
|
|
|
|
|
|
|
||||||||
Ambulatory Care |
|
$ |
19 |
|
|
$ |
27 |
|
|
$ |
40 |
|
|
$ |
35 |
|
Hospital Operations and other |
|
|
130 |
|
|
|
90 |
|
|
|
262 |
|
|
|
200 |
|
Conifer |
|
|
3 |
|
|
|
5 |
|
|
|
5 |
|
|
|
8 |
|
Total |
|
$ |
152 |
|
|
$ |
122 |
|
|
$ |
307 |
|
|
$ |
243 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
(1) Net operating revenues include the impact of implicit price concessions and bad debts |
Additional Supplemental Non-GAAP disclosures
Table #1 – Reconciliations of Net Income Available to Common Shareholders to Adjusted Net Income Available from Continuing Operations to Common Shareholders (Unaudited) |
||||||||||||||||
(Dollars in millions except per share amounts) |
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Net income available to |
|
$ |
38 |
|
|
$ |
119 |
|
|
$ |
178 |
|
|
$ |
216 |
|
Net income (loss) from discontinued operations |
|
|
— |
|
|
|
(1 |
) |
|
|
1 |
|
|
|
(1 |
) |
Net income from continuing operations |
|
|
38 |
|
|
|
120 |
|
|
|
177 |
|
|
|
217 |
|
Less: Impairment and restructuring charges, and acquisition-related costs |
|
|
(57 |
) |
|
|
(20 |
) |
|
|
(73 |
) |
|
|
(40 |
) |
Litigation and investigation costs |
|
|
(18 |
) |
|
|
(22 |
) |
|
|
(38 |
) |
|
|
(35 |
) |
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
1 |
|
|
|
15 |
|
|
|
0 |
|
|
|
15 |
|
Loss from early extinguishment of debt |
|
|
(66 |
) |
|
|
(31 |
) |
|
|
(109 |
) |
|
|
(54 |
) |
Tax impact of above items |
|
|
15 |
|
|
|
5 |
|
|
|
21 |
|
|
|
18 |
|
Adjusted net income available from continuing operations to common shareholders |
|
$ |
163 |
|
|
$ |
173 |
|
|
$ |
376 |
|
|
$ |
313 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings per share from continuing operations |
|
$ |
0.35 |
|
|
$ |
1.11 |
|
|
$ |
1.63 |
|
|
$ |
2.00 |
|
Less: Impairment and restructuring charges, and acquisition-related costs |
|
|
(0.52 |
) |
|
|
(0.18 |
) |
|
|
(0.64 |
) |
|
|
(0.37 |
) |
Litigation and investigation costs |
|
|
(0.17 |
) |
|
|
(0.20 |
) |
|
|
(0.33 |
) |
|
|
(0.32 |
) |
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
0.01 |
|
|
|
0.14 |
|
|
|
— |
|
|
|
0.14 |
|
Loss from early extinguishment of debt |
|
|
(0.61 |
) |
|
|
(0.29 |
) |
|
|
(0.96 |
) |
|
|
(0.50 |
) |
Tax impact of above items |
|
|
0.14 |
|
|
|
0.05 |
|
|
|
0.18 |
|
|
|
0.16 |
|
Adjusted diluted earnings per share from continuing operations |
|
$ |
1.50 |
|
|
$ |
1.59 |
|
|
$ |
3.38 |
|
|
$ |
2.89 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average basic shares outstanding (in thousands) |
|
|
107,790 |
|
|
|
106,822 |
|
|
|
107,636 |
|
|
|
106,566 |
|
Weighted average dilutive shares outstanding (in thousands) |
|
|
108,750 |
|
|
|
108,569 |
|
|
|
114,054 |
|
|
|
108,317 |
|
Additional Supplemental Non-GAAP disclosures
Table #2 – Reconciliations of Net Income Available to Common Shareholders to Adjusted EBITDA (Unaudited) |
||||||||||||||||
(Dollars in millions) |
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Net income available to |
|
$ |
38 |
|
|
$ |
119 |
|
|
$ |
178 |
|
|
$ |
216 |
|
Less: Net income available to noncontrolling interests |
|
|
(141 |
) |
|
|
(138 |
) |
|
|
(281 |
) |
|
|
(263 |
) |
Income (loss) from discontinued operations, net of tax |
|
|
— |
|
|
|
(1 |
) |
|
|
1 |
|
|
|
(1 |
) |
Income from continuing operations |
|
|
179 |
|
|
|
258 |
|
|
|
458 |
|
|
|
480 |
|
Income tax expense |
|
|
(86 |
) |
|
|
(61 |
) |
|
|
(185 |
) |
|
|
(106 |
) |
Loss from early extinguishment of debt |
|
|
(66 |
) |
|
|
(31 |
) |
|
|
(109 |
) |
|
|
(54 |
) |
Other non-operating income (expense), net |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
9 |
|
Interest expense |
|
|
(222 |
) |
|
|
(235 |
) |
|
|
(449 |
) |
|
|
(475 |
) |
Operating income |
|
|
553 |
|
|
|
586 |
|
|
|
1,201 |
|
|
|
1,106 |
|
Litigation and investigation costs |
|
|
(18 |
) |
|
|
(22 |
) |
|
|
(38 |
) |
|
|
(35 |
) |
Net gains on sales, consolidation and deconsolidation of facilities |
|
|
1 |
|
|
|
15 |
|
|
|
— |
|
|
|
15 |
|
Impairment and restructuring charges, and acquisition-related costs |
|
|
(57 |
) |
|
|
(20 |
) |
|
|
(73 |
) |
|
|
(40 |
) |
Depreciation and amortization |
|
|
(216 |
) |
|
|
(221 |
) |
|
|
(419 |
) |
|
|
(445 |
) |
Adjusted EBITDA |
|
$ |
843 |
|
|
$ |
834 |
|
|
$ |
1,731 |
|
|
$ |
1,611 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net operating revenues |
|
$ |
4,638 |
|
|
$ |
4,954 |
|
|
$ |
9,383 |
|
|
$ |
9,735 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net income available to |
|
|
0.8 |
% |
|
|
2.4 |
% |
|
|
1.9 |
% |
|
|
2.2 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) |
|
|
18.2 |
% |
|
|
16.8 |
% |
|
|
18.4 |
% |
|
|
16.5 |
% |
Additional Supplemental Non-GAAP disclosures Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow from Continuing Operations (Unaudited) |
||||||||
(Dollars in millions) |
|
2022 |
||||||
|
|
Q2 |
|
YTD |
||||
Net cash provided by operating activities |
|
$ |
119 |
|
|
$ |
347 |
|
Purchases of property and equipment |
|
|
(152 |
) |
|
|
(307 |
) |
Free cash flow |
|
|
(33 |
) |
|
|
40 |
|
Add back: Medicare Advance Repayments |
|
|
281 |
|
|
|
475 |
|
Free cash flow, excluding repayment of Medicare Advances |
|
$ |
248 |
|
|
$ |
515 |
|
|
|
|
|
|
||||
Net cash used in investing activities |
|
$ |
(140 |
) |
|
$ |
(200 |
) |
Net cash used in financing activities |
|
$ |
(33 |
) |
|
$ |
(1,160 |
) |
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
119 |
|
|
$ |
347 |
|
Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(42 |
) |
|
|
(98 |
) |
Adjusted net cash provided by operating activities from continuing operations |
|
|
161 |
|
|
|
445 |
|
Purchases of property and equipment |
|
|
(152 |
) |
|
|
(307 |
) |
Adjusted free cash flow – continuing operations |
|
|
9 |
|
|
|
138 |
|
Add back: Medicare Advance Repayments |
|
|
281 |
|
|
|
475 |
|
Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances |
|
$ |
290 |
|
|
$ |
613 |
|
(Dollars in millions) |
|
2021 |
||||||
|
|
Q2 |
|
YTD |
||||
Net cash provided by operating activities |
|
$ |
245 |
|
|
$ |
779 |
|
Purchases of property and equipment |
|
|
(122 |
) |
|
|
(243 |
) |
Free cash flow |
|
|
123 |
|
|
|
536 |
|
Add back: Medicare Advance Repayments |
|
|
152 |
|
|
|
152 |
|
Free cash flow, excluding repayment of Medicare Advances |
|
$ |
275 |
|
|
$ |
688 |
|
|
|
|
|
|
||||
Net cash used in investing activities |
|
$ |
(50 |
) |
|
$ |
(195 |
) |
Net cash used in financing activities |
|
$ |
(142 |
) |
|
$ |
(836 |
) |
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
245 |
|
|
$ |
779 |
|
Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(34 |
) |
|
|
(85 |
) |
Adjusted net cash provided by operating activities from continuing operations |
|
|
279 |
|
|
|
864 |
|
Purchases of property and equipment |
|
|
(122 |
) |
|
|
(243 |
) |
Adjusted free cash flow – continuing operations |
|
|
157 |
|
|
|
621 |
|
Add back: Medicare Advance Repayments |
|
|
152 |
|
|
|
152 |
|
Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances |
|
$ |
309 |
|
|
$ |
773 |
|
Additional Supplemental Non-GAAP disclosures Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA (Unaudited) |
||||||||||||||||
(Dollars in millions) |
|
Q3’22 |
|
FY 2022 |
||||||||||||
|
|
Low |
|
High |
|
Low |
|
High |
||||||||
Net income available to |
|
$ |
100 |
|
|
$ |
135 |
|
|
$ |
371 |
|
|
$ |
546 |
|
Less: Net income available to noncontrolling interests |
|
|
(125 |
) |
|
|
(145 |
) |
|
|
(590 |
) |
|
|
(630 |
) |
Income tax expense |
|
|
(90 |
) |
|
|
(100 |
) |
|
|
(375 |
) |
|
|
(410 |
) |
Interest expense |
|
|
(225 |
) |
|
|
(215 |
) |
|
|
(890 |
) |
|
|
(880 |
) |
Loss from early extinguishment of debt(1) |
|
|
— |
|
|
|
— |
|
|
|
(109 |
) |
|
|
(109 |
) |
Other non-operating income (expense), net |
|
|
— |
|
|
|
5 |
|
|
|
— |
|
|
|
10 |
|
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(2) |
|
|
(30 |
) |
|
|
(20 |
) |
|
|
(200 |
) |
|
|
(150 |
) |
Depreciation and amortization |
|
|
(205 |
) |
|
|
(215 |
) |
|
|
(840 |
) |
|
|
(860 |
) |
Loss from divested and closed businesses (i.e., health plan businesses) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
775 |
|
|
$ |
825 |
|
|
$ |
3,375 |
|
|
$ |
3,575 |
|
|
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations |
|
$ |
100 |
|
|
$ |
135 |
|
|
$ |
371 |
|
|
$ |
546 |
|
Net operating revenues |
|
$ |
4,700 |
|
|
$ |
4,900 |
|
|
$ |
19,000 |
|
|
$ |
19,400 |
|
Net income available to |
|
|
2.1 |
% |
|
|
2.8 |
% |
|
|
2.0 |
% |
|
|
2.8 |
% |
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) |
|
|
16.5 |
% |
|
|
16.8 |
% |
|
|
17.8 |
% |
|
|
18.4 |
% |
(1) |
The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2022. |
|
|
||
(2) |
The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
Additional Supplemental Non-GAAP disclosures Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available from Continuing Operations to Common Shareholders (Unaudited) |
||||||||||||||||
(Dollars in millions except per share amounts) |
|
Q3’22 |
|
FY 2022 |
||||||||||||
|
|
Low |
|
High |
|
Low |
|
High |
||||||||
Net income available to |
|
$ |
100 |
|
|
$ |
135 |
|
|
$ |
371 |
|
|
$ |
546 |
|
Net income from discontinued operations, net of tax |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net income from continuing operations |
|
|
100 |
|
|
|
135 |
|
|
|
371 |
|
|
|
546 |
|
Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) |
|
|
(30 |
) |
|
|
(20 |
) |
|
|
(200 |
) |
|
|
(150 |
) |
Loss from early extinguishment of debt(2) |
|
|
— |
|
|
|
— |
|
|
|
(109 |
) |
|
|
(109 |
) |
Loss from divested and closed businesses (i.e., health plan businesses) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Tax impact of above items |
|
|
5 |
|
|
|
5 |
|
|
|
35 |
|
|
|
25 |
|
Adjusted net income available from continuing operations to common shareholders |
|
$ |
125 |
|
|
$ |
150 |
|
|
$ |
645 |
|
|
$ |
780 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings per share from continuing operations |
|
$ |
0.91 |
|
|
$ |
1.23 |
|
|
$ |
3.35 |
|
|
$ |
4.91 |
|
Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements |
|
|
(0.28 |
) |
|
|
(0.18 |
) |
|
|
(1.79 |
) |
|
|
(1.34 |
) |
Loss from early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(0.97 |
) |
|
|
(0.97 |
) |
Loss from divested and closed businesses (i.e., health plan businesses) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Tax impact of above items |
|
|
0.05 |
|
|
|
0.05 |
|
|
|
0.31 |
|
|
|
0.22 |
|
Adjusted diluted earnings per share from continuing operations |
|
$ |
1.14 |
|
|
$ |
1.36 |
|
|
$ |
5.80 |
|
|
$ |
7.00 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average basic shares outstanding (in thousands) |
|
|
108,000 |
|
|
|
108,000 |
|
|
|
108,000 |
|
|
|
108,000 |
|
Weighted average dilutive shares outstanding (in thousands) |
|
|
110,000 |
|
|
|
110,000 |
|
|
|
112,000 |
|
|
|
112,000 |
|
(1) |
The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
|
|
||
(2) |
The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2022. |
Additional Supplemental Non-GAAP disclosures Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow – Continuing Operations and Outlook Adjusted Free Cash Flow – Continuing Operations (Unaudited) |
||||||||
|
|
|
|
|
||||
(Dollars in millions) |
|
FY 2022 |
||||||
|
|
Low |
|
High |
||||
Net cash provided by operating activities |
|
$ |
1,100 |
|
|
$ |
1,400 |
|
Purchases of property and equipment – continuing operations |
|
|
(725 |
) |
|
|
(775 |
) |
Free cash flow – continuing operations |
|
|
375 |
|
|
|
625 |
|
Add back: |
|
|
|
|
||||
Medicare Advance Repayments |
|
|
880 |
|
|
|
880 |
|
Payroll Tax Deferral Payments |
|
|
128 |
|
|
|
128 |
|
Free cash flow excluding repayments of Medicare Advances and Deferred Payroll Tax Payments |
|
$ |
1,383 |
|
|
$ |
1,633 |
|
|
|
|
|
|
||||
|
|
|
|
|
||||
Net cash provided by operating activities |
|
$ |
1,100 |
|
|
$ |
1,400 |
|
Less: Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1) |
|
|
(200 |
) |
|
|
(150 |
) |
Net cash used in operating activities from discontinued operations |
|
|
— |
|
|
|
— |
|
Adjusted net cash provided by operating activities – continuing operations |
|
|
1,300 |
|
|
|
1,550 |
|
Purchases of property and equipment – continuing operations |
|
|
(725 |
) |
|
|
(775 |
) |
Adjusted free cash flow – continuing operations(2) |
|
|
575 |
|
|
|
775 |
|
Add back: |
|
|
|
|
||||
Medicare Advance Repayments |
|
|
880 |
|
|
|
880 |
|
Payroll Tax Deferral Payments |
|
|
128 |
|
|
|
128 |
|
Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances and Deferred Payroll Tax Payments |
|
$ |
1,583 |
|
|
$ |
1,783 |
|
(1) |
The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. |
|
|
||
(2) |
The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720006095/en/
Investor Contact
469-893-2387
william.mcdowell@tenethealth.com
Media Contact
469-893-2640
mediarelations@tenethealth.com
Source:
FAQ
What were Tenet Healthcare's Q2 2022 earnings results?
How did the cybersecurity incident affect Tenet's operations?
What is Tenet Healthcare's outlook for FY 2022?